================================================================================
PHARMACY SALES PRESCRIPTIVE RECOMMENDATIONS
Generated: 2025-10-22 00:12:32
================================================================================

üì¶ INVENTORY MANAGEMENT RECOMMENDATIONS:

  ‚úì HIGH PRIORITY REORDERS (Top 5 by demand):
    ‚Ä¢ RETASAR (LOSARTAN POTASSIUM) 50MG: Reorder when stock falls below 393 units
      - Maintain safety stock of 201 units
      - Expected demand (30 days): 373 units
    ‚Ä¢ NOVASARTAN (LOSARTAN K) 50MG FC TAB: Reorder when stock falls below 373 units
      - Maintain safety stock of 192 units
      - Expected demand (30 days): 450 units
    ‚Ä¢ OHHIRA&#039;S RED OMX PROBIOTICS CAP: Reorder when stock falls below 166 units
      - Maintain safety stock of 71 units
      - Expected demand (30 days): 268 units
    ‚Ä¢ BIOGESIC (PARACETAMOL) 500MG TAB: Reorder when stock falls below 169 units
      - Maintain safety stock of 99 units
      - Expected demand (30 days): 20 units
    ‚Ä¢ APPEVIT (BUCLIZINE HCL+B-COMPLEX+IRON) CAP: Reorder when stock falls below 146 units
      - Maintain safety stock of 77 units
      - Expected demand (30 days): 222 units

üìã ORDERING STRATEGY RECOMMENDATIONS:

  ‚úì OPTIMAL ORDER QUANTITIES (Top 5 products):
    ‚Ä¢ RETASAR (LOSARTAN POTASSIUM) 50MG: Order 2365 units every 77 days
      - This minimizes total cost to $28,468.95/year
    ‚Ä¢ BIOGESIC (PARACETAMOL) 500MG TAB: Order 1747 units every 60 days
      - This minimizes total cost to $46,236.11/year
    ‚Ä¢ APPEVIT (BUCLIZINE HCL+B-COMPLEX+IRON) CAP: Order 799 units every 38 days
      - This minimizes total cost to $110,907.45/year
    ‚Ä¢ NOVASARTAN (LOSARTAN K) 50MG FC TAB: Order 1919 units every 97 days
      - This minimizes total cost to $18,189.87/year
    ‚Ä¢ OHHIRA&#039;S RED OMX PROBIOTICS CAP: Order 407 units every 22 days
      - This minimizes total cost to $338,891.42/year

üí∞ BUDGET ALLOCATION RECOMMENDATIONS:

  ‚úì PRIORITIZE INVESTMENT IN:
    ‚Ä¢ RETANIX (CETIRIZINE) 10MG TAB: Allocate 350388 units ($852,492.02)
      - Expected profit: $712,336.82

üíµ PRICING & DISCOUNT RECOMMENDATIONS:

  ‚úì MAINTAIN/INCREASE DISCOUNTS FOR:
    ‚Ä¢ BETTER C (ASCORBIC ACID ) 500MG TAB: Current discount 0.0% is highly efficient
      - Generates 9500.0 units per dollar of discount
    ‚Ä¢ MULTICAPS: Current discount 0.0% is highly efficient
      - Generates 7575.0 units per dollar of discount
    ‚Ä¢ LIVERAIDE (SILYMARIN) CAP: Current discount 0.0% is highly efficient
      - Generates 971.4 units per dollar of discount

  ‚úì REDUCE/ELIMINATE DISCOUNTS FOR:
    ‚Ä¢ DUOTRAM (PARA + TRAMA HCL) 325MG/37.5MG TAB: Low efficiency (41.0 units/$)
      - Consider reducing discount from 0.2%
    ‚Ä¢ ZUNAMYN (SULTAMICILLIN) 750MG TAB: Low efficiency (41.0 units/$)
      - Consider reducing discount from 0.0%
    ‚Ä¢ FREDTOR (ATORVASTATIN) 40MG TAB 100&#039;s: Low efficiency (41.0 units/$)
      - Consider reducing discount from 0.6%

üìà SALES GROWTH OPPORTUNITIES:

  ‚úì PROMOTE HIGH-MARGIN PRODUCTS:
    ‚Ä¢ #EXP2025-03-30: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ #EXP2025-03-31: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ #EXP2026-07-30: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ #EXP2027-05-24: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ ALCIFLORA (BACILLUS CLAUSII) 5ML: 100.0% margin
      - Increase visibility and marketing for this product

  ‚úì PRODUCTS WITH GROWTH POTENTIAL:
    ‚Ä¢ RETASAR (LOSARTAN POTASSIUM) 50MG: Steady demand (27.4 units/day)
      - Consider promotional campaigns to boost sales
    ‚Ä¢ BIOGESIC (PARACETAMOL) 500MG TAB: Steady demand (10.1 units/day)
      - Consider promotional campaigns to boost sales
    ‚Ä¢ APPEVIT (BUCLIZINE HCL+B-COMPLEX+IRON) CAP: Steady demand (10.0 units/day)
      - Consider promotional campaigns to boost sales

‚öôÔ∏è OPERATIONAL EFFICIENCY RECOMMENDATIONS:

  ‚úì INVESTIGATE ANOMALOUS SALES DAYS:
    ‚Ä¢ 104 days showed unusual patterns
    ‚Ä¢ Review these dates for:
      - Stock-outs or supply issues
      - Unexpected demand spikes
      - Data entry errors
    ‚Ä¢ 2024-09-18: Sales $118,645.44 (Score: -0.79)
    ‚Ä¢ 2024-03-21: Sales $66,970.49 (Score: -0.75)
    ‚Ä¢ 2024-03-18: Sales $87,535.88 (Score: -0.73)

üèóÔ∏è RESOURCE PLANNING RECOMMENDATIONS:

  ‚úì PREPARE FOR NEXT 90 DAYS:
    ‚Ä¢ Total storage space needed: 71,602 cubic feet
    ‚Ä¢ Total capital required: $1,053,232.37
    ‚Ä¢ Ensure adequate:
      - Warehouse capacity
      - Working capital/credit lines
      - Staff for inventory management

üë• CUSTOMER SEGMENT STRATEGY:

  ‚úì CUSTOMER GROUP INSIGHTS:
    ‚Ä¢ Regular:
      - Sales: $15,776,728.36
      - Profit Margin: 21.1%
      - Units Sold: 503,499
    ‚Ä¢ Senior/PWD:
      - Sales: $4,839,320.01
      - Profit Margin: 13.2%
      - Units Sold: 197,277

üéØ QUICK WINS (Immediate Actions):

  ‚úì THIS WEEK:
    1. Review and adjust reorder points for top 10 products
    2. Implement EOQ-based ordering for high-volume items
    3. Analyze anomalous sales days and document findings

  ‚úì THIS MONTH:
    1. Optimize discount strategy based on efficiency analysis
    2. Reallocate budget to high-margin products
    3. Set up automated reorder alerts at calculated ROP levels
    4. Train staff on new inventory management procedures

  ‚úì THIS QUARTER:
    1. Implement full resource planning system
    2. Develop customer segment-specific marketing campaigns
    3. Review and optimize supplier relationships
    4. Establish KPIs and monitoring dashboards

‚ö†Ô∏è RISK MITIGATION:

  ‚úì MONITOR CLOSELY:
    ‚Ä¢ High demand variability products:
      - RETASAR (LOSARTAN POTASSIUM) 50MG: CV = 168.8%
        ‚Üí Maintain higher safety stock
      - NOVASARTAN (LOSARTAN K) 50MG FC TAB: CV = 170.9%
        ‚Üí Maintain higher safety stock
      - RETANIX (CETIRIZINE) 10MG TAB: CV = 415.5%
        ‚Üí Maintain higher safety stock